Nausea and reduced food intake compound each other
In these trials, the medication was marketed under the brand name Zepbound for obesity and Mounjaro for type 2 diabetes
503B: A Side-by-Side Comparison Key Regulatory Updates Affecting 503A and 503B (20232025) USP Updates (Nov 2023): Revised USP , , , and are now in effect, changing beyond-use date rules, training requirements, and hazardous drug handling
Typical titration Start: 2.5 mg once weekly for 4 weeks (a starter dose to help your body adjust) Increase to: 5 mg once weekly Then, if needed and tolerated, increase by 2.5 mg every 4 weeks to 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg once weekly Your prescriber will tailor the dose based on blood sugar targets (for Mounjaro), weight response (for Zepbound), and side effects
With appropriate management strategies, most patients can successfully continue tirzepatide therapy while minimizing digestive side effects